Given this background, the purpose of this study was to explore the relationship between radiographic response alone using the mRECIST measurement method or combined with AFP response and pCR, in patients with HCC receiving systemic therapy with a combination of a TKI and an anti–PD-1 antibody followed by surgical resection. The gene discussed is RPL17; the disease is hepatocellular carcinoma.